Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus

• Cristina Mussini,

  Affiliation Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy

  ⨯
• Patrizia Lorenzini,

  Affiliation National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

  ⨯
• Massimo Puoti,

  Affiliation Clinic of Infectious Diseases, Maggiore Hospital, Milan, Italy

  ⨯
• Miriam Lichtner,

  Affiliation Clinic of Infectious Diseases, La Sapienza University, Rome, Italy

  ⨯
• Giuseppe Lapadula,

  Affiliation Department of Infectious Diseases, San Gerardo Hospital, Monza, Italy

  ⨯
• Simona Di Giambenedetto,

  Affiliation Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy

  ⨯
• Andrea Antinori,

  Affiliation National Institute for Infectious Diseases L. Spallanzani, Rome, Italy

  ⨯
• Giordano Madeddu,

  Affiliation Clinica delle Malattie Infettive, Università di Sassari, Sassari, Italy

  ⨯
• Alessandro Cozzi-Lepri,

  Affiliation Department of Infection & Population Health Division of Population Health, Hampstead Campus, University College London, London, United Kingdom

  ⨯
• Antonella d’Arminio Monforte,

  Affiliation Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, Milan, Italy

  ⨯
• Andrea De Luca ,

  * E-mail: a.deluca@ao-siena.toscana.it

  Affiliation Division of Infectious Diseases, Department of Medical Biotechnologies, University of Siena and Siena University Hospital, Siena, Italy

  ⨯
• ICONA Foundation study group

  ¶Membership of the ICONA Foundation study group is provided in the Acknowledgments.

  ⨯